Cite
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
MLA
Drew, Yvette, et al. “Phase 2 Multicentre Trial Investigating Intermittent and Continuous Dosing Schedules of the Poly(ADP-Ribose) Polymerase Inhibitor Rucaparib in Germline BRCA Mutation Carriers with Advanced Ovarian and Breast Cancer.” British Journal of Cancer, vol. 114, no. 12, June 2016, p. e21. EBSCOhost, https://doi.org/10.1038/bjc.2016.133.
APA
Drew, Y., Ledermann, J., Hall, G., Rea, D., Glasspool, R., Highley, M., Jayson, G., Sludden, J., Murray, J., Jamieson, D., Halford, S., Acton, G., Backholer, Z., Mangano, R., Boddy, A., Curtin, N., & Plummer, R. (2016). Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. British Journal of Cancer, 114(12), e21. https://doi.org/10.1038/bjc.2016.133
Chicago
Drew, Yvette, Jonathan Ledermann, Geoff Hall, Daniel Rea, Ros Glasspool, Martin Highley, Gordon Jayson, et al. 2016. “Phase 2 Multicentre Trial Investigating Intermittent and Continuous Dosing Schedules of the Poly(ADP-Ribose) Polymerase Inhibitor Rucaparib in Germline BRCA Mutation Carriers with Advanced Ovarian and Breast Cancer.” British Journal of Cancer 114 (12): e21. doi:10.1038/bjc.2016.133.